ASX Announcements

Expiry of 900,000 options without exercise or conversion

Living Cell Technologies Limited (LCT) today announced the Preliminary Final Report (Appendix 4E) on the financial results for the year ended 30 June 2021.

The Board continues to focus on securing an arrangement which will allow shareholders the possibility of getting a return on their investment in the company. It is in active discussions with several entities to achieve this goal.

In the meantime, the company continues to put in place a range of measures to conserve cash.

LCT continues to conserve cash, ending the quarter with a cash balance of $1,568,928 compared to $2,240,007 in the previous quarter.

Net operating cash flow in the quarter was ($671,062) compared to ($188,893) in the previous quarter. Receipts from grants and tax incentives were $84,644, lower than the previous quarter of $186,901.

Operating payments this quarter were higher at $756,767 compared to last quarter of $375,895. This included the research and development amount of $428,649 that included the settlement of NZ$400,000 to the University of Auckland for the Migraine and Obesity projects. (Please refer to our announcement on 29 March 2021).